Efficacy and Safety of Q8003 in the Management of Post-bunionectomy Pain

NCT ID: NCT00560183

Last Updated: 2012-05-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 256 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-11-30
• Study Completion Date: 2008-04-30

Brief Summary

This study will explore the efficacy and safety of a fixed dose combination of morphine and oxycodone for management of acute postoperative pain. The study will explore the efficacy dose response and dosing interval required to maintain adequate analgesia at each tested dosage strength.

Detailed Description

This study is a randomized, double-blind, placebo-controlled, rising-dose/by-cohort study of the efficacy and safety of Q8003 in inpatients with acute pain following unilateral bunionectomy surgery. Patients in each dosing group will receive either Q8003 (approximately 50 per dosing group) or placebo (approximately 13 per dosing group), determined by random sequential assignment and blinded to patients and managing Investigators. Dosing groups will be enrolled sequentially in ascending order; only one dosing group will be open at a time for enrollment.

Conditions

Postoperative Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

1

Group Type: EXPERIMENTAL

Q8003 (morphine sulfate and oxycodone hydrochloride)

Intervention Type: DRUG

Capsules, four different mg dosage strengths

2

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Capsules

Interventions

Q8003 (morphine sulfate and oxycodone hydrochloride)

Capsules, four different mg dosage strengths

Intervention Type: DRUG

Placebo

Capsules

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patient is scheduled for bunionectomy surgery and is willing to stay in the study center for at least 48 hours from the initial dose of study medication post surgery.
• Females must be non-pregnant, non-lactating, and practicing an acceptable method of birth control, or be surgically sterile or postmenopausal (amenorrhea for ≥12 months).
• Patient has normal laboratory values or abnormal values judged not clinically significant by the Investigator for clinical chemistry and hematology (< 1.5 ULN).
• Patient is in general good health based on physical examination, medical history and clinically acceptable results for the following assessments: vital signs and a 12-lead electrocardiogram (ECG).
• Patient gives written informed consent and is able to understand the requirements of the study, adhere to the study restrictions, and be available for the required follow-up assessment.

Exclusion Criteria

• Patient has a current acute or chronic disease that would interfere with evaluations of postoperative Q8003 efficacy or safety.
• Patient has a history of poor tolerance to short term opiate use in prior surgeries, based on patient self-report.
• Patient used opiates continuously (including tramadol) for more than five days in the past year.
• Patient has a history of pulmonary, cardiovascular, neurologic, endocrine, hepatic, gastrointestinal, or kidney disease or therapy that, in the opinion of the Investigator, would jeopardize the patient's well-being by participation in this study.
• Patient has positive HIV serology or signs of HIV infection or AIDS.
• Patient has positive HBsAg or HCV antibody.
• Patient is currently receiving any medications that are not at a stable dose (the same dose for >2 month prior to date of surgery).
• Patient is currently receiving muscle relaxants, antipsychotic drugs, monoamine oxidase inhibitors, or any medications for the treatment of depression.
• Patient has used systemic corticosteroids within previous fourteen (14) days.
• Patient was dosed with another investigational drug within 30 days prior to the Screening Visit.
• Patient has current evidence of alcohol abuse (regularly drinks more than 4 units of alcohol per day; 1 unit = ½ pint of beer, 1 glass of wine, or 1 ounce of spirit).
• Patient has a history of abusing licit or illicit drug substances within five (5) years of study entry.
• Patient is obese with a body mass index >32.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

QRxPharma Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Warren Stern, Ph.D.

Role: STUDY_DIRECTOR

QRxPharma Inc.

Locations

Advanced Clinical Research Institute

Anaheim, California, United States

Chesapeake Research Group

Pasadena, Maryland, United States

Advanced Regional Center for Foot and Ankle Care

Altoona, Pennsylvania, United States

Scirex Research Center

Houston, Texas, United States

Lifetree Clinical Research

Salt Lake City, Utah, United States

Jean Brown Research

Salt Lake City, Utah, United States

Countries

United States

Other Identifiers

Q8003-007

Identifier Type: -

Identifier Source: org_study_id